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Loss of 5-hydroxymethylcytosine is a frequent event
in peripheral T-cell lymphomas
Mutations in the epigenetic regulators TET2, IDH2, and
DNMT3A are frequent in peripheral T-cell lymphomas
(PTCL), especially in those derived from T follicular helper
(TFH) cells. However, the consequences of these alterations
on overall levels of 5-hydroxymethylcytosine (5hmC) and
5-methylcytosine (5mC) are unknown. Here, using an
immunohistochemical method to detect 5hmC and 5mC in
situ in PTCL samples, we showed that PTCL tumor cells
had lower 5hmC levels than normal T cells, independently
of the presence of TET2, IDH2, or DNMT3A mutations.
We observed the loss of 5hmC, not only in TFH-derived
PTCL, but also in various nodal or extranodal PTCL enti-
ties, with the exception of hepatosplenic T-cell lym-
phomas. These results suggest that 5hmC loss is a general
event in PTCL lymphomagenesis.
TET2, IDH2, and DNMT3A are three genes whose prod-
ucts are involved in the control of cytosine methylation and
are frequently mutated in myeloid neoplasms. TET2 is a α-
ketoglutarate-dependent dioxygenase involved in 5mC
hydroxylation to form 5hmC, an epigenetic mark involved
in cytosine demethylation.1 Mutation of IDH2 confers a
neomorphic activity to this enzyme, leading to the produc-
tion of D-2 hydroxyglutarate, an oncometabolite that is
able to inhibit α-ketoglutarate-dependent dioxygenases,
including TET2.1 In acute myeloid leukemia, TET2 and
IDH2mutations are mutually exclusive, and are both asso-
ciated with decreased 5hmC levels and a similar methyla-
tion profile1. DNMT3A is involved in de novo methylation
and DNMT3A mutations affect its activity.1,2 Although the
consequences of these three mutations on DNA methyla-
tion levels are unclear, they are all expected to additively
result in deregulated methylation and decreased 5hmC lev-
els. 
These three genes are frequently mutated in PTCL, espe-
cially in angioimmunoblastic T-cell lymphomas (AITL) in
which TET2mutations are detected in up to 80% of cases,
IDH2 in 30%, and DNMT3A in 30%.3-8 Although TET2
and DNMT3A mutations can be found in several PTCL
entities, they appear to be enriched in AITL and nodal
PTCL with TFH phenotype, whereas IDH2 mutations are
only present in AITL.6,7 Although somatic, TET2 and
DNMT3A mutations can be found not only in tumor cells,
but also in CD34+ hematopoietic progenitors or reactive
cells, suggesting they may be an early event during lym-
phomagenesis,3,6 whereas IDH2mutations likely occur as a
second event.9 Moreover, IDH2mutations frequently coex-
ist with TET2mutations in AITL.6,8,9 Altogether, at least one
of these mutations is present in 80% of TFH-derived lym-
phomas, but their functional consequences on 5hmC/5mC
are poorly understood.10 
We explored the epigenetic consequences of these muta-
tions by assessing 5hmC and 5mC levels in six reactive
lymphoid tissues (2 lymph nodes and 4 tonsils), and a series
of 71 PTCL with TET2, IDH2 and DNMT3A sequencing
data selected within the framework of a multicenter T-cell
lymphoma consortium (Tenomic) (see Online Supplementary
Material). 
Due to the common paucity in tumor cells in AITL, we
chose to evaluate 5hmC and 5mC in AITL using an estab-
lished immunohistochemistry assay involving anti-5hmC
and anti-5mC antibodies on de-paraffinized tissue sections
which allows an in situ evaluation that can semi-quantita-
tively discriminate 5hmC and 5mC levels in tumor cells ver-
sus those from the surrounding environment. Indeed, a
common, characteristic histopathological feature of AITL is
the prominent tumor environment, with tumor cells usual-
ly representing only a minor component. 
We first analyzed the distribution of 5hmC and 5mC in
normal lymph nodes and tonsils, stained with anti-5hmC
and anti-5mC antibodies (Figure 1 and Online
Supplementary Figure S1). Cells in the interfollicular areas
with a high T-cell content, were mostly positive for 5hmC,
whereas almost all the germinal center cells were negative
(Figure 1A). However, a few scattered cells were strongly
positive for 5hmC. These positive cells were identified as
follicular dendritic cells, macrophages and PD1-positive T
cells, which are likely TFH cells given their phenotype and
their location inside the germinal center (Figure 1B-D).
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Table 1. Description of the PTCL cases included in the study. 
Number of cases 5hmC in tumor cells 5mC in tumor cells 
AITL 30 0 30
Mutated AITL 14 0 14 
WT AITL 16 0 16
PTCL-NOSa 10 0 10 
ALK-ALCLb 3 0 3 
ALK+ALCL 3 0 3 
EATL 2 0 4 
MEITL 16 0c 16
HSTL 3 3 3 
ENKTCL 4 0 4 
Total 71 3 52
Mutated cases 19 0 19
WT cases 52 3 33
“Mutated” designates cases with identified TET2, IDH2, and/or DNMT3Amutations in tumor tissues, WT designates the absence of TET2, IDH2,  or DNMT3Amutations, PTCL-
NOS: peripheral T-cell lymphoma not otherwise specified, ALK-ALCL: ALK-negative anaplastic large cell lymphoma, ALK+ALCL:  ALK-positive anaplastic large cell lym-
phoma, EATL: enteropathy-associated T-cell lymphoma (type 1); MEITL: monomorphic epitheliotropic intestinal T-cell lymphoma; HSTL: hepatosplenic T-cell lymphoma,
ENKTCL extranodal NK/T-cell lymphoma, nasal type. aincluding four TET2, DNMT3A and/or IDH2 mutated PTCL-NOS. bincluding one TET2 mutated ALK-ALCL. cincluding
four cases in which a minority (<20%) of tumor cells presented down regulated but detectable levels of 5hmC.
These results suggest that normal TFH cells have a high
level of 5hmC. In contrast, 5mC staining showed a high
level of 5mC in germinal centers and in the interfollicular
zone (Online Supplementary Figure S2).
We then examined the levels of 5hmC and 5mC in AITL
samples representative of various mutational patterns for
TET2, IDH2, and DNMT3A. Staining for 5hmC showed a
variable number of positive cells among samples, parallel-
ing the variable content of reactive and tumor cells in AITL.
5hmC-positive cells were generally scattered with morpho-
logical features suggestive of cells from the microenviron-
ment (Figure 2A,B). We confirmed the lack of detectable
5hmC in neoplastic cells by double immunohistochemical
staining which showed the absence of 5hmC in PD1-posi-
tive AITL tumor cells (Figure 2C). We also confirmed the
absence of detectable 5hmC in IDH2-mutated AITL tumor
cells using an antibody specifically directed against the
R172K mutant form of the IDH2 protein in IDH2R172K-
mutated AITL samples9 (Figure 2D). Among the 30 cases of
AITL, nine carried TET2mutations, 12 IDH2mutations, six
DNMT3Amutations, and 16 cases were wild-type for these
three genes, five of them being sequenced by targeted deep
sequencing at a mean coverage of 1219X to increase the
sensitivity of the sequencing method (see the Online
Supplementary Methods) and limit the risk of missing a muta-
tion (Table 1 and Online Supplementary Tables S1 and S2).
No 5hmC was observed in the neoplastic cells of any of the
cases (Figure 2E-G). Together with the presence of 5hmC in
normal TFH, these findings indicate the loss of 5hmC in
AITL tumor cells regardless of the mutational status of
these three epigenetic modifier genes. The presence of
5hmC-positive cells in the environment in every AITL case
highlights the accuracy of using in situ methods such as
immunohistochemistry or cell-sorted samples for studying
epigenetic changes in AITL tumor cells.
This observation led us to extend our examination of
5hmC levels to other PTCL entities. As for AITL, there was
no detectable 5hmC in the tumor cells of almost all inves-
tigated PTCL samples including ten PTCL-not otherwise
specified, three ALK-positive anaplastic large cell lym-
phomas, three ALK-negative anaplastic large cell lym-
phomas, two enteropathy-associated T-cell lymphomas, 16
monomorphic epitheliotropic intestinal T-cell lymphomas
and four extranodal NK/T cell lymphomas, nasal type
(Table 1 and Online Supplementary Tables S1, S2 and S3)
with the exception of three of three hepatosplenic T-cell
lymphomas, in which neoplastic cells in the sinuses stained
positively for 5hmC (Online Supplementary Figure S3).
Detection of 5hmC in hepatosplenic T-cell lymphomas is
intriguing but does not seem to be associated with the pres-
ence of a SETD2mutation or γδ origin, as SETD2 and γδ T-
cell receptor-positive monomorphic epitheliotropic intes-
tinal T-cell lymphomas showed low levels of 5hmC (Online
Supplementary Table S3). A variable proportion of reactive
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Figure 1. Characterization of cells positive for 5-hydroxymethylcytosine and 5-methylcytosine in a representative case of reactive tonsil with follicular hyper-
plasia. (A) 5hmC immunohistochemistry staining showing scattered positive cells within a germinal center (GC) contrasting with the positivity of most cells in the
mantle zone (MZ) or interfollicular cells (inset). (B) Scattered 5hmC positive cells (brown) in the germinal center are CD163 positive (red, white arrow), or are
binucleated as typical for follicular dendritic cells (black arrow).  (C and D) Most cells stained for 5hmC (brown) in the germinal center are also PD1-positive (red)
by double staining for PD1. Original magnification: objective X10 (A) and X40 (B, C) and X100 (D). 
cells were strongly stained by the 5hmC antibody in all
PTCL samples, and served as internal positive controls. 
In contrast, virtually all cells, including neoplastic cells, of
all PTCL samples stained for 5mC. We failed to demon-
strate any variation in the level of 5mC among samples
including any dependency on the PTCL entity, within the
limit of the sensitivity of the method (Figure 2H,I).
TET2 or IDH2 mutations are expected to impair 5hmC
formation in mutated AITL. We did indeed demonstrate
the lack of 5hmC in the neoplastic T cells of most PTCL,
but the lack of detectable 5hmC was not restricted to
TET2-, IDH2-, or DNMT3A-mutated AITL. However, this
immunohistochemical assay was recently used in acute
myeloid leukemia samples, in which TET2 mutated sam-
ples displayed lower 5hmC levels than wild-type samples,11
in adult T-cell leukemia/lymphoma, in which aggressive
forms showed lower 5hmC levels than indolent forms12
and in B-cell lymphomas, in which the level of 5hmC
depends on the cell of origin.13 These three independent
reports suggest that immunohistochemistry is a reliable
method for evaluating 5hmC levels in hematologic malig-
nancies.
Although it is a step toward cytosine demethylation, the
exact function of 5hmC in normal and malignant biology is
still elusive. Loss of 5hmC occurs in several types of cancer
in which it is associated with tumor progression12,14 or a
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Figure 2. Characterization of cells
positive for 5-hydroxymethylcytosine
and 5-methylcytosine in mutated or
wild-type  angioimmuniblastic T-cell
lymphoma. (A-D) TET2, IDH2, and
DNMT3A mutated AITL (case 397) (A)
Hematoxylin and eosin stain (HES), (B)
5hmC immunohistochemistry  stain-
ing showing a few scattered cells with
nuclear staining suggestive of cells of
the environment. (C) Double
immunostaining showing that the
PD1-positive cells with membrane
staining (brown) do not have
detectable levels of 5hmC in their
nuclei (red). (D) In this case with a
IDH2R172K mutation, neoplastic
cells with granular cytoplasmic stain-
ing for the IDH2R172K mutant (red)
lack 5hmC (brown). (E-G) TET2, IDH2,
and DNMT3A WT AITL (case 007) (E)
Hematoxylin and eosin stain (HES).
Similar observations were made in a
representative case of WT AITL with
(F) scattered cells positive for 5hmC
staining, (G) lack of detectable 5hmC
(brown) in neoplastic PD1-positive
lymphocytes (red). (H and I) 5mC is
found in the nuclei of virtually all cells
in cases 397 and 007. Original magni-
fication: objective X40. 
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proliferative state.15 In PTCL, however, loss of 5hmC was
essentially constant irrespective of the proliferation index
(Online Supplementary Figure S4). The mechanism for the
decrease of 5hmC levels in PTCL in the absence of genetic
alterations in the TET2, DNMT3A, and IDH2 epigenetic
modifiers needs to be clarified, focusing particularly on
whether it could involve undetected genomic anomalies in
these genes, metabolic causes inhibiting TET function, TET
expression down-regulation, TET1 or TET3 alterations or
yet other mechanisms.1
Regardless of the mechanism, our findings highlight the
high frequency of epigenetic changes in PTCL, which may
not be restricted to patients bearing mutations in TET2,
DNMT3A, or IDH2. Whether these epigenetic anomalies
could be specifically targeted, using hypomethylating
agents or other drugs, and which patients could benefit
from these treatments, need to be determined in further
studies. 
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